Abstract:Key points Electrophysiological characterization of Q1412X‐CFTR, a C‐terminal truncation mutation of cystic fibrosis transmembrane conductance regulator (CFTR) associated with the severe form of cystic fibrosis (CF), reveals a gating defect that has not been reported previously. Mechanistic investigations of the gating deficit in Q1412X‐CFTR suggest that the reduced open probability in Q1412X‐CFTR is the result of a disruption of the function of the second ATP binding site (or site 2) in the nucleotide binding domains (NBDs). Detailed comparisons of several mutations with different degrees of truncation in the C‐terminal region of NBD2 reveal the importance of the last two beta‐strands in NBD2 for maintaining proper gating functions. The results of the present study also show that the application of clinically‐approved drugs (VX‐770 and VX‐809) can greatly enhance the function of Q1412X, providing in vitro evidence for a therapeutic strategy employing both reagents for patients bearing Q1412X or similar truncation mutations. AbstractCystic fibrosis (CF) is caused by loss‐of‐function mutations of cystic fibrosis transmembrane conductance regulator (CFTR), a phosphorylation‐activated but ATP‐gated chloride channel. Based on the molecular mechanism of CF pathogenesis, disease‐associated mutations are categorized into six classes. Among them, Class VI, whose members include some of the C‐terminal truncation mutations such as Q1412X, is defined as decreased membrane expression because of a faster turnover rate. In the present study, we characterized the functional properties of Q1412X‐CFTR, a severe‐form premature stop codon mutation. We confirmed previous findings of a ∼90% decrease in membrane expression but found a ∼95% reduction in the open probability (Po). Detailed kinetic studies support the idea that the gating defect is the result of a dysfunctional ATP‐binding site 2 in the nucleotide binding domains (NBDs). Because the Q1412X mutation results in a deletion of the last two beta‐strands in NBD2 and the whole C‐terminal region, we further characterized truncation mutations with different degrees of deletion in this segment. Mutations that completely or partially remove the C‐terminus of CFTR at the same time as keeping an intact NBD2 (i.e. D1425X and S1455X) assume gating function almost identical to that of wild‐type channels. However, the deletion of the last beta‐strand in the NBD2 (i.e. N1419X) causes gating dysfunction that is milder than that of Q1412X. Thus, normal CFTR gating requires structural integrity of NBD2. Moreover, our observation that clinically‐approved VX‐809 (Lumacaftor, Vertex Pharmaceuticals, Boston, MA, USA) and VX‐770 (Ivacaftor, Vertex Pharmaceuticals, Boston, MA, USA) significantly enhance the overall function of Q1412X‐CFTR provides the conceptual basis for the treatment of patients carrying this mutation.

Function and regulation of TRPM7, as well as intracellular magnesium content, are altered in cells expressing ΔF508-CFTR and G551D-CFTR

THE STRUCTURAL AND FUNCTIONAL IMPORTANCE OF TYPE II DIVERGENT AMINO ACIDS IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

Three Charged Amino Acids in the Outer Vestibule of CFTR Stabilize the Open Pore Architecture

The identification of the key residues E829 and R845 involved in transient receptor potential melastatin 2 channel gating

A TRPV4 Channel C-terminal Folding Recognition Domain Critical for Trafficking and Function.

Transient receptor potential melastatin 7 and their modulators

CFTR function, pathology and pharmacology at single-molecule resolution

TRPM7 silencing attenuates Mg2+ influx in cardiac myoblasts, H9c2 cells

TRPM channels in health and disease

Novel gain-of-function mutants identify a critical region within CFTR membrane-spanning domain 2 controlling cAMP-dependent and ATP-independent channel activation

Distinct calcium regulation of TRPM7 mechanosensitive channels at plasma membrane microdomains visualized by FRET-based single cell imaging

TRPM7 activity drives human CD4 T-cell activation and differentiation in a magnesium dependent manner

The Inhibition of the Membrane-Bound Transcription Factor Site-1 Protease (MBTP1) Alleviates the p.Phe508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Defects in Cystic Fibrosis Cells

On the Mechanism of Gating Defects Caused by the R117H Mutation in Cystic Fibrosis Transmembrane Conductance Regulator

TRPM7 is the central gatekeeper of intestinal mineral absorption essential for postnatal survival

TRPM7 is critical for short-term synaptic depression by regulating synaptic vesicle endocytosis

Natural and synthetic modulators of SK (K(ca)2) potassium channels inhibit magnesium-dependent activity of the kinase-coupled cation channel TRPM7

CFTR: a cysteine at position 338 in TM6 senses a positive electrostatic potential in the pore

Structural Mechanisms for Defective CFTR Gating Caused by the Q1412X Mutation, a Severe Class VI Pathogenic Mutation in Cystic Fibrosis.

Exploring therapeutic potential: Targeting TRPM7 in neurodegenerative diseases

A Cataract-Causing Mutation in the TRPM3 Cation Channel Disrupts Calcium Dynamics in the Lens